PURPOSE
To assess radiation oncologists' perceptions of training and research opportunities in the fields of genomics, bioinformatics, and immunology.
MATERIALS AND METHODS
A 13-item electronic survey was sent to 101 radiation oncology department chairs and administrators. A separate 30-item electronic survey was sent to 132 members of the American Society for Radiation Oncology Science Council as well as to 565 members of the Association of Residents in Radiation Oncology. Survey responses were collected, and results were analyzed using descriptive statistics.
RESULTS
Twenty-six department chairs and 91 general respondents submitted responses. Among general respondents, 69% were current trainees and 31% had completed training. The majority of respondents (92%) were affiliated with an academic/university main campus. Approximately half of respondents (43% to 53%) reported no prior formal training in bioinformatics, genomics, or immunology. More than half of department chairs (54% to 58%) and general respondents (57% to 63%) thought that current training opportunities in these areas were absolutely or moderately insufficient. A majority of respondents (53% to 65%) thought that additional training in these areas would provide opportunity for career advancement, and 80% could identify a current or future research project that additional training in these fields would allow them to pursue. More than half of respondents expressed interest in attending a formal training course, and the majority of department chairs (22 of 26 [85%]) reported that they would probably or definitely send trainees or faculty members to a formal training course.
CONCLUSION
Among radiation oncologists surveyed, there is a perceived lack of current training opportunities in bioinformatics, genomics, and immunology. A majority of respondents reported an interest in obtaining additional training in these areas and believed that training would provide opportunity for career advancement.
[1]
C. Drake,et al.
Inhibitors of the PD-1 Pathway in Tumor Therapy
,
2018,
The Journal of Immunology.
[2]
E. Lander,et al.
Lessons from the Cancer Genome
,
2013,
Cell.
[3]
P. Tran,et al.
Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop
,
2018,
Journal of Immunotherapy for Cancer.
[4]
Issam El Naqa,et al.
Introduction to Big Data in Radiation Oncology: Exploring Opportunities for Research, Quality Assessment, and Clinical Care.
,
2016,
International journal of radiation oncology, biology, physics.
[5]
Tarek Mekhail,et al.
Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer
,
2017,
The New England journal of medicine.
[6]
M. Berger,et al.
Delivering on the promise of precision cancer medicine
,
2016,
Genome Medicine.
[7]
C. N. Coleman,et al.
Precision Oncology and Genomically Guided Radiation Therapy, A Report From the ASTRO/AAPM/NCI Precision Medicine Conference
,
2017
.